I have heterozygous c.187C>G and c.745G>A variants; what is their clinical significance and what should I do?

Clinical Significance and Management of Heterozygous c.187C>G and c.745G>A Variants

Critical First Step: Identify the Gene

You must first determine which gene harbors these variants, as the clinical significance and management depend entirely on the specific gene involved. Without knowing the gene name, these variant designations (c.187C>G and c.745G>A) cannot be interpreted for clinical actionability, cancer risk, or other health implications 1.

Immediate Actions Required

Obtain Complete Genetic Testing Report

• Request the full laboratory report that includes the gene name, protein change nomenclature (p. notation), variant classification (pathogenic, likely pathogenic, variant of uncertain significance, etc.), and genome build coordinates 1
• The report should specify whether these variants are in the same gene (compound heterozygous) or different genes 2
• Confirm the testing methodology used and whether the variants were confirmed on a second sample 3

Verify Variant Classification

• Each variant should have a clear pathogenicity classification according to ACMG/AMP guidelines (pathogenic, likely pathogenic, uncertain significance, likely benign, or benign) 1
• The laboratory report must provide evidence supporting the classification, including population frequency data, functional studies, and segregation analysis if available 1

Gene-Specific Considerations

If These Are CHEK2 Variants

The provided evidence extensively covers CHEK2 variants, though neither c.187C>G nor c.745G>A are specifically mentioned in the CHEK2 literature provided. If these variants are in CHEK2:

• For truncating variants: Moderate increased risk for breast cancer (OR ~2.0), with higher risks for bilateral disease and male breast cancer 1
• For missense variants: Generally lower penetrance than truncating variants, with specific variants like p.(Ile157Thr) showing weaker associations 1
• Colorectal cancer risk: Low-to-moderate increased risk (OR 1.8-2.8), particularly in familial cases, but may not reach clinical actionability threshold in isolation 1
• Prostate cancer risk: Increased risk for aggressive/metastatic disease, particularly with c.1100del variant 1

If Compound Heterozygous in a Liver Disease Gene

If these variants are compound heterozygous (both in the same gene, one from each parent) in a gene causing liver disease:

• Determine mutation types: A combination of one missense and one stop codon mutation typically results in more severe disease than two missense mutations 2
• Prognosis implications: Stop codon-containing compound heterozygous mutations are associated with shorter liver survival, poorer treatment response, and may require early liver transplantation evaluation 2
• Monitoring intensity: More frequent hepatocellular carcinoma screening (every 6 months) and liver function tests (every 3-6 months) for stop codon-containing genotypes 2

Essential Next Steps

Genetic Counseling Referral

• Arrange consultation with a board-certified genetic counselor or medical geneticist to interpret the specific variants in the context of your personal and family history 1, 3
• Discuss inheritance pattern, recurrence risks for family members, and reproductive implications 3, 2
• Determine if parental testing is indicated to establish phase (cis vs. trans) if variants are in the same gene 3, 2

Family History Assessment

• Document three-generation pedigree focusing on cancers or conditions associated with the identified gene 1
• Identify at-risk family members who may benefit from cascade testing 1

Clinical Surveillance Planning

• Surveillance recommendations depend entirely on the specific gene, variant pathogenicity, and family history 1, 2
• For cancer predisposition genes, enhanced screening protocols may include earlier initiation and increased frequency of imaging 1, 2
• For metabolic or liver disease genes, organ-specific monitoring protocols should be implemented 2

Critical Pitfalls to Avoid

• Do not assume clinical significance without gene identification: The same nucleotide position in different genes has completely different implications 1
• Do not rely solely on online databases: Variant interpretation requires expert review of multiple evidence types and may change over time as new data emerges 1
• Do not overlook compound heterozygosity: If both variants are in the same gene, the combined effect may be more severe than either variant alone 2
• Do not delay genetic counseling: Professional interpretation is essential for accurate risk assessment and management planning 1, 3